Beta-thalassemia is the most common form of Thalassaemia. It is associated with A number of serious complications, including amputations, blindness, and kidney failure. The disease is also associated with autoimmune diseases such as lupus, psoriasis, and rheumatoid arthritis.
Beta-thalassemia is the most common form of Thalassaemia. It is associated with A number of serious complications, including amputations, blindness, and kidney failure. The disease is also associated with autoimmune diseases such as lupus, psoriasis, and rheumatoid arthritis.
Beta-thalassemia is the most common form of Thalassaemia. It is associated with A number of serious complications, including amputations, blindness, and kidney failure. The disease is also associated with autoimmune diseases such as lupus, psoriasis, and rheumatoid arthritis.
Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. 2005.
Natural history of type
1 diabetes. Diabetes. 54(2):25-31.
Berard R. Approach to the child with joint inflammation. Pediatr Clin N Am. 2012;59:245-62.
1. Rund D, Rachmilewitz E. -Thalassemia. N Engl J Med. 2005;353:1135-46. 2. Sofro AS. Molecular pathology of beta thalassemia in Indonesia. South East Asian J Trop Med Public Health.1995;26:2212214. 3. Cappelini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassemia. Edisi ke-2. Cyprus: Thalassaemia International Federation.2008.p.20-32,106-20. 4. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11- 5. Cao A, Galanello R. Beta-thalassemia. Genetics in Medicine. 2010. p. 61 76. 6. Piomelli S. The management of patients with Cooleys anemia: transfusions and splenectomy. Semin Hematol. 1995;32(4):2628. 7. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. N Engl J Med.1994;331:567-73. 8. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen Ar. Complications of beta thalassemia major in North America. Blood. 2004;104:34-9. 9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and Complications in Patients with Thalassemia Major Treated with Transfusion and Deferoxamine. Haematologica.2004;89:1187-93. 10. Cohen AR. New Advances in Iron Chelation Therapy. Hematology. 2006;42- 7. 11. Hoffbrand AV, Cohen A, Hershko C. Role of Deferiprone in Chelation Therapy for Transfusional Iron Overload. Blood. 2003;102(1): 17-24. 12. World Health Organization/ thalassemia International Federation. Joint meeting on the prevention and control of haemoglobinopathies. Nicosia- cyprus: World Health Organization/Thalassemia International Federation,1994:20. 13. Porter JB. Iron Toxicity and Clinical Sequelae. Br J Hematol. 2001; 115: 239- 52. 14. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004, 104:34-39. 15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187- 1193. 16. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574. 17. Vermylen C. What is New in Iron Overload?. Eur J Pediatr 2008; 167: 377- 81. 18. Davis BA, OSulivian C. Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejectioon fraction in the of thalasemia major. Blood 2004; 104:263-9. 19. Arijanty L, Nasar SS. Masalah Nutrisi pada thalassemia. Sari Pediatri. 2003;5: 21-26. 20. Fung EB. Nutritional deficiencies in patients with thalassemia. Annals of the New York Academy of Sciences. 2010.p. 188-96 21. Khurana A, Katyal S, Marwaha RK. Psychosocial burden in thalassemia. Indian J Pediatr .2006;73(10):87780.